Evidence-based recommendations on nivolumab (Opdivo) for treating squamous cell carcinoma of the head and neck in adults who have had platinum-based chemotherapy.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: The guidance will be updated when the data collection period has ended (expected to be September 2019, when 4-year follow-up data from CheckMate-141 are available). Nivolumab will continue to be available through the Cancer Drugs Fund while the guidance is being updated, as part of the managed access agreement.